CSat Investment Advisory’s Biogen BIIB Stock Holding History

CSat Investment Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$942K	Buy	3,369 +166	+5%	+$44.8K	0.79%	38
2020 Q4	$784K	Sell	3,203 -288	-8%	-$74.3K	0.73%	52
2020 Q3	$991K	Buy	3,491 +929	+36%	+$259K	0.09%	103
2020 Q2	$686K	Buy	2,562 +231	+10%	+$69.4K	0.08%	133
2020 Q1	$738K	Sell	2,331 -114	-5%	-$34.6K	0.16%	90
2019 Q4	$726K	Sell	2,445 -114	-4%	-$31.6K	0.19%	97
2019 Q3	$595K	Buy	2,559 +2,203	+619%	+$513K	0.19%	92
2019 Q2	$83K	Buy	356 +340	+2,125%	+$78.5K	0.03%	330
2019 Q1	$4K	Buy	16 +2	+14%	+$630	﹤0.01%	510
2018 Q4	$4K	Buy	14 +5	+56%	+$1.6K	﹤0.01%	496
2018 Q3	$3K	Sell	9 -1	-10%	-$344	﹤0.01%	501
2018 Q2	$3K	Buy	+10	New	+$2.81K	﹤0.01%	499

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CSat Investment Advisory's BIIB Position: Q1 2021 in Review

CSat Investment Advisory increased its Biogen (BIIB) stake by 5.2% in Q1 2021, buying an estimated $44.8K and bringing the position to 3,369 shares worth $942K. The position accounts for 0.79% of the portfolio, ranked #38.

CSat Investment Advisory first reported a position in BIIB in Q2 2018 and has held it in 12 quarters since. The position peaked at $991K in Q3 2020. 1,094 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

CSat Investment Advisory held 3,369 shares of Biogen worth $942K as of Q1 2021.
CSat Investment Advisory bought 166 Biogen shares in Q1 2021, an estimated $44.8K.
Biogen made up 0.79% of CSat Investment Advisory's portfolio in Q1 2021, its #38 holding.
CSat Investment Advisory first reported a position in Biogen in Q2 2018 and has held it in 12 quarters since.
CSat Investment Advisory's Biogen position peaked at $991K in Q3 2020.
1,094 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.